Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
This study has been completed.
Study NCT00004393 Information provided by Office of Rare Diseases (ORD)
First Received: October 18, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tourette Syndrome
Additional conditions recognized in this trial
Syndrome
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Disease
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Mental Disorders
Mental Disorders Diagnosed in Childhood
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Pathologic Processes
Tic Disorders
Interventions listed in this trial
risperidone
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
National Center for Research Resources (NCRR)
Yale University
Back to top of Main Content
